Literature DB >> 9715953

Geographic distribution and clinical description of leishmaniasis cases in Peru.

C M Lucas1, E D Franke, M I Cachay, A Tejada, M E Cruz, R D Kreutzer, D C Barker, S H McCann, D M Watts.   

Abstract

Studies were conducted from 1986 through 1993 to further define the geographic distribution and relative importance of different species of Leishmania as a cause of leishmaniasis in Peru. Patients with a clinical diagnosis of cutaneous and/or mucosal or diffuse cutaneous leishmaniasis were enrolled at the Naval Medical Research Institute Detachment (NAMRID) Laboratory in Lima, the Tropical Disease Clinic at San Marcos University Daniel A. Carrión, the Central Military Hospital, and a Ministry of Health hospital in Cusco, Peru. Clinical features, lesion aspirates, and biopsy tissue were obtained from each patient. All specimens were collected and assayed separately, including multiple specimens from some of the same patients for Leishmania parasites by inoculating aliquots of either aspirates or biopsy tissue suspensions onto Senekji's blood agar medium. Stocks of Leishmania isolates were used to prepare promastigotes to produce extracts for identifying the Leishmania species by the cellulose acetate electrophoresis enzyme technique. A total of 351 isolates of Leishmania were obtained from 350 patients who were infected primarily in the low and high jungle of at least 15 different Departments of Peru. Of the 351 isolates, 79% were identified as L. (V.) braziliensis, 7% as L. (V.) guyanensis, 10% as L. (V.) peruviana, 2% as L. (V.) lainsoni, and 1.7% as L. (L.) amazonensis. The clinical form of disease varied depending on the species of Leishmania, with L. (V.) braziliensis being associated most frequently with cutaneous, mucosal ulcers and mixed cutaneous and mucosal disease, and L. (V) peruviana, L. (V.) guyanensis, L. (V.) lainsoni with cutaneous lesions. Leishmania (L.) amazonensis was isolated from six patients, three with cutaneous lesions, one with mucosal lesions, and two with diffuse cutaneous lesions. Among all of the leishmaniasis cases, males were affected more frequently, and cases occurred among patients less than 10 to more than 51 years of age. These data further defined the geographic distribution and the relative frequency of Leishmania species associated with different clinical forms of leishmaniasis in Peru.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715953     DOI: 10.4269/ajtmh.1998.59.312

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  43 in total

1.  Use of FTA cards for direct sampling of patients' lesions in the ecological study of cutaneous leishmaniasis.

Authors:  Hirotomo Kato; Abraham G Cáceres; Tatsuyuki Mimori; Yuka Ishimaru; Amal S M Sayed; Megumi Fujita; Hiroyuki Iwata; Hiroshi Uezato; Lenin N Velez; Eduardo A L Gomez; Yoshihisa Hashiguchi
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Leishmania (Viannia) lainsoni (Silveira et al. 1987): ultrastructural aspects of the parasite and skin lesion in experimentally infected hamster (Mesocricetus auratus).

Authors:  José R Corrêa; Reginaldo P Brazil; Maurilio J Soares
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

3.  Simultaneous infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian patient with cutaneous leishmaniasis.

Authors:  Nicolas Veland; Braulio Mark Valencia; Milena Alba; Vanessa Adaui; Alejandro Llanos-Cuentas; Jorge Arevalo; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

4.  Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.

Authors:  Marlene Jara; Braulio Mark Valencia; Vanessa Adaui; Milena Alba; Rachel Lau; Jorge Arevalo; Alejandro Llanos-Cuentas; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2015-10-19       Impact factor: 2.345

5.  Natural Leishmania infection of Lutzomyia auraensis in Madre de Dios, Peru, detected by a fluorescence resonance energy transfer-based real-time polymerase chain reaction.

Authors:  Hugo O Valdivia; Maxy B De Los Santos; Roberto Fernandez; G Christian Baldeviano; Victor O Zorrilla; Hubert Vera; Carmen M Lucas; Kimberly A Edgel; Andrés G Lescano; Kirk D Mundal; Paul C F Graf
Journal:  Am J Trop Med Hyg       Date:  2012-07-16       Impact factor: 2.345

6.  Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis.

Authors:  Andrea K Boggild; Ana P Ramos; Diego Espinosa; Braulio M Valencia; Nicolas Veland; Cesar Miranda-Verastegui; Jorge Arevalo; Donald E Low; Alejandro Llanos-Cuentas
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

7.  Leishmania (Viannia) species identification on clinical samples from cutaneous leishmaniasis patients in Peru: assessment of a molecular stepwise approach.

Authors:  Nicolas Veland; Andrea K Boggild; Cristian Valencia; Braulio M Valencia; Alejandro Llanos-Cuentas; Gert Van der Auwera; Jean-Claude Dujardin; Jorge Arevalo
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

8.  CXCL10 production by human monocytes in response to Leishmania braziliensis infection.

Authors:  Diego A Vargas-Inchaustegui; Alison E Hogg; Gianfranco Tulliano; Alejandro Llanos-Cuentas; Jorge Arevalo; Janice J Endsley; Lynn Soong
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Geographic clustering of leishmaniasis in northeastern Brazil.

Authors:  Albert Schriefer; Luiz H Guimarães; Paulo R L Machado; Marcus Lessa; Hélio A Lessa; Ednaldo Lago; Guilherme Ritt; Aristóteles Góes-Neto; Ana L F Schriefer; Lee W Riley; Edgar M Carvalho
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

10.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.